Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor, Quadrant Capital Advisors.
The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated insulin delivery system and its connected, auto-titrating insulin pen.
Get the full story at our sister site, Drug Delivery Business News.
The post Bigfoot Biomedical raises $37m in Series B appeared first on MassDevice.